sfondo pallini







Developing and commercializing specialized therapies for the treatment of rare diseases by using the patient’s own blood

Latest News

View all

EryDel Announces Top-line Results from Phase 3 ATTeST Trial Demonstrating Significant ...

July 12, 2021

Read more

Taking part in the First International Campaign Raising Awareness for Ataxia ...

December 04, 2020

Read more
img ufficio

Our Technology

EryDel’s proprietary platform technology is an easy to use, fast and automatic bedside procedure, to encapsulate small and large molecules including therapeutic enzymes in patients’ red blood cells. The cells are immediately re-infused into patients providing prolonged half-life in circulation, reduced immunogenicity, better tolerability and predictable vascular distribution.


A late Stage
and Broad Pipeline

Our People

About us
luca-benatti +

Luca Benatti
Chief Executive Officer

giovanni-mambrini +

Giovanni Mambrini
Chief Operating Officer

ronan-gannon +

Ronan Gannon
Chief Commercial Officer

esin-kosal +

Esin Kosal
Senior Vice President Global Regulatory Affairs

guenter-r-janhofer +

Guenter R. Janhofer
Chief Medical Officer